A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
about
T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective VaccinesPotential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerNotch signaling deregulation in multiple myeloma: A rational molecular targetMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsImmunotherapy strategies for multiple myeloma: the present and the futureInnovative agents in multiple myelomaPreclinical validation of interleukin 6 as a therapeutic target in multiple myelomaDevelopment of Novel Immunotherapies for Multiple MyelomaSiltuximab (CNTO 328): a promising option for human malignanciesRenal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migrationEvaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialMicroenvironmental regulation of therapeutic response in cancerTPL2 kinase regulates the inflammatory milieu of the myeloma nicheRepositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapyToll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.Impact of interleukin-6 in hematological malignancies.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.The development of potential antibody-based therapies for myelomaProinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and AmyloidosisImmunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys.Cancer prevention and therapy through the modulation of the tumor microenvironment.Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expressionAn inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathwaySignaling between tumor cells and the host bone marrow microenvironment.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Monoclonal antibodies as therapeutics in human malignancies.Siltuximab: first global approval.From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Clinical development of siltuximab.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
P2860
Q26768539-9DFE745D-61F5-4551-AF65-2C6D9EC6B233Q26769917-E83831DF-F2D2-46A0-B22F-0CD6788B4565Q26797283-4EDF91B3-5DC9-476E-9434-6889D8CD4CA5Q26799104-307278F4-12F9-4912-8547-656AA9257A1AQ26822754-9A8DF9DE-3A14-43F2-9967-2DBBF6A72BAFQ27021939-658B3913-B2B6-4845-8691-F24BB0F0DE0BQ27022493-2B3546C2-10C0-4524-9939-8BE8429295C5Q27027729-98704CF4-1B27-44EB-9C1A-D1212425F90AQ28066890-F0759957-5263-4BC1-ACDD-E1EE5122CB38Q28082572-047F760B-20F5-4DCD-965D-BB39288EE481Q30275870-192137ED-EC76-48A5-8BD1-EF8D1AFF0ED6Q30660919-0063AAE8-5F8A-4518-9F80-7DA5885BBF75Q33411075-D8318198-9A90-4FAC-B73A-62B15FC7435AQ33418036-E6E6E6C0-333E-4F26-A02B-7DFAC8C279ACQ33420197-7F6A0737-BE06-48D2-B1ED-43334F820007Q33429980-4E1599F0-29D5-4530-ADFD-46C8E6855366Q33654609-78768620-CB8F-4AB2-8218-7F26F18BF998Q33714724-4EDE930F-7F91-4F89-B404-FA8EAE488CEBQ33866426-968D0D0D-6628-440E-B3B6-82EBC839ED66Q33978723-7BAF477D-6A10-4964-AB4F-302BAD5FEF6FQ34009070-D6A7C21D-3063-43E1-815C-FC0B6A3422B9Q34387624-35BB3C42-6B90-499F-80E0-6F9552789C01Q34486159-E2CF482F-1FF2-45FE-AD5B-2C805A9F13B1Q34996693-B779BC8A-AF59-413E-A791-82FF5F0AD710Q35788245-6DDD39B5-A497-4C36-8CE1-B8548BA20C45Q36150377-F3D4DC12-B61A-40AA-B956-B6DB45673857Q36473988-F527729A-CD96-4662-B2F0-8AE3530405EAQ36499879-EFED9AC0-6CE2-41D0-B864-162BC10BBC88Q37058267-BB2B9BE5-67D2-4861-AB9D-175F2838819BQ37117208-DCF37CA3-69C7-4C54-B9C0-4ED20D437400Q37688978-7AC36BD4-7411-43A6-82A1-B0B60AFC4EF8Q38138849-FE1673F1-9D31-449D-85E5-6BA9141126F2Q38205856-ACEF7DAF-AF2D-44EF-A08D-E92DD4807E3EQ38206275-3F6B60AE-E9CE-407A-B8D8-A43C160E41BDQ38222680-897D642D-3357-4C5C-AAE8-EEA32941D563Q38336406-35385EA8-283E-48EF-A6A6-EB272CFE8DBDQ38489678-56F1F298-BFE8-4A04-B8C6-C8D9DFDAB2ACQ38601582-82AA874F-34E0-4B47-A10F-B85761BA10B9Q38630472-B3301D0C-E749-489B-BCB9-9774193A8FA5Q38658328-4B3B5031-BED7-4D7A-B4E6-6FA5461F9471
P2860
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@en
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@nl
type
label
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@en
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@nl
prefLabel
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@en
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@nl
P2093
P2860
P356
P1476
A phase 2 multicentre study of ...... r refractory multiple myeloma.
@en
P2093
Amrita Krishnan
Brett Hall
Britte Kranenburg
George Somlo
Helgi van de Velde
Peter M Voorhees
Pierre W Wijermans
Richard C Frank
Robert F Manges
P2860
P304
P356
10.1111/BJH.12266
P407
P577
2013-02-25T00:00:00Z